LARVOL VIEW Top 100 is a curated list of the most influential Digital Opinion Leaders (DOLs) in oncology on Twitter. Our methodology selects and ranks DOLs based on online influence, offline activity, and the opinions of other verified oncologists.
Top oncologists are turning to Twitter for important conversations with their peers. In fact, there are almost 500 tweets every week posted by verified oncologists related to trending news in cancer research, trials, treatments, and drug development. This trend is growing, and a group of over 1,200 Digital Opinion Leaders (DOLs) has emerged as an important voice in the community.
Today, we recognize the leading voices among DOLs with the 2021 LARVOL VIEW Top 100 Most Influential Oncologists on Twitter. This curated list represents the 100 oncologists with the largest influence on the cancer conversation on Twitter, balanced with analysis of their offline activity in the field and the input of their peers.
The 100 oncologists on our list stand out as those who are leading the way online and taking advantage of the full potential of Twitter as a tool to educate and inspire their peers, and the medical community.
To identify voices of influence on Twitter, the LARVOL team started by tracking oncology news on Twitter, then built out a list of oncologists who were actively sharing and reacting to that news. We then implemented a weighted methodology to select and rank DOLs based on online influence, offline activity, and the opinions of other verified oncologists. Each score is weighted equally to produce the final LARVOL VIEW Top 100 ranking.
1. Online Rank: Measured by Twitter Followers and Reactions to oncology news (posts comments and quote tweets, as captured by VIEW)
2. Offline Rank: Measured by participation in ongoing Clinical Trials and Citations from the last 5 years (Google Scholar)
3. Peer Survey Rank: Nominations from peers in LARVOL VIEW Top 100 survey
The oncologists recognized on this year’s list were celebrated at LARVOL’s “Night at the Museum,” a unique event held in virtual reality on the final night of ASCO’s 2021 Virtual Meeting.
The LARVOL VIEW Top 100 Most Influential Oncologists on Twitter is powered by VIEW, the first social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and DOLs. VIEW also presents a feed of curated oncology news from Twitter alongside the reactions of verified oncologists.
Contact us for more information on VIEW and download your list of the top 100 influential voices in oncology.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network